Current Report Filing (8-k)
25 Mars 2016 - 9:25PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 24, 2016
Portola Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-35935
|
|
20-0216859
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
270 E. Grand Avenue
South San Francisco, California
|
|
94080
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (650) 246-7300
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the
following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01 Other Events.
On March 24, 2016, Portola Pharmaceuticals, Inc., issued a press release announcing the topline results from its Phase 3 APEX Trial of Betrixaban for the
prevention of blood clots in acute medically ill patients. A copy of the press release is attached as Exhibit 99.1 to this report.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits
|
|
|
Number
|
|
Description of Document
|
|
|
99.1
|
|
Press Release entitled Portola Pharmaceuticals Announces Topline Results from Phase 3 APEX Trial of Betrixaban for Prevention of Blood Clots in Acute Medically Ill Patients dated March 24, 2016.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Portola Pharmaceuticals, Inc.
|
|
|
|
Dated: March 25, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Mardi C. Dier
|
|
|
|
|
|
|
Mardi C. Dier
|
|
|
|
|
|
|
Executive Vice President and Chief Financial Officer
|
EXHIBIT INDEX
|
|
|
Number
|
|
Description of Document
|
|
|
99.1
|
|
Press Release entitled Portola Pharmaceuticals Announces Topline Results from Phase 3 APEX Trial of Betrixaban for Prevention of Blood Clots in Acute Medically Ill Patients dated March 24, 2016.
|
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Portola Pharmaceuticals Inc (NASDAQ): 0 recent articles
Plus d'articles sur Portola Pharmaceuticals Inc